ERBB2 and breast cancer: Based on several clinical and pathological factors, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status, BC is routinely divided into several subtypes in clinical implementation (6, 7).